The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous coronary intervention (PCI) and stenting is still controversial. This study evaluates the impact of oral administration of prednisone or sirolimus to prevent restenosis.
Cassese, S., De Luca, G., Ribichini, F., Cernigliaro, C., Sansa, M., Versaci, F., et al. (2014). ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: A patient-level meta-analysis of randomized trials. ATHEROSCLEROSIS, 237(2), 410-417 [10.1016/j.atherosclerosis.2014.09.021].
ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: A patient-level meta-analysis of randomized trials
VERSACI, FRANCESCO;
2014-12-01
Abstract
The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous coronary intervention (PCI) and stenting is still controversial. This study evaluates the impact of oral administration of prednisone or sirolimus to prevent restenosis.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2014 Ath RAMSES Cooperation_Main.pdf
accesso solo dalla rete interna
Descrizione: articolo principale
Licenza:
Copyright dell'editore
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
